
The race to the RSV market is fully underway, and on Monday, Bavarian Nordic began sprinting – at least in the direction of the Chinese market.
Bavarian Nordic announced that it had signed a license and commercialization deal with Shanghai-based biotech company Nuance Pharma for the Danish firm’s RSV vaccine candidate, MVA-BN RSV, for people over the age of 60.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app